TERT promoter mutation is an objective clinical marker for disease progression in chondrosarcoma
Open Access
- 1 November 2021
- journal article
- research article
- Published by Elsevier BV in Laboratory Investigation
- Vol. 34 (11), 2020-2027
- https://doi.org/10.1038/s41379-021-00848-0
Abstract
No abstract availableKeywords
Funding Information
- Stiftelsen Tornspiran (201809)
- Karolinska Institutet
- Cancerfonden (JCIA-190003, PJ-190299)
- Cancerföreningen i Stockholm (184053)
This publication has 15 references indexed in Scilit:
- Frequency of TERT promoter mutations in human cancersNature Communications, 2013
- Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2Nature Genetics, 2011
- Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndromeNature Genetics, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Consequences of Telomerase Inhibition by BIBR1532 on Proliferation and Chemosensitivity of Chondrosarcoma Cell LinesCancer Investigation, 2008
- Telomerase Reverse Transcriptase Subunit Expression Is Associated with Chondrosarcoma MalignancyClinical Orthopaedics and Related Research, 2004
- Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells.1999
- The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoterHuman Molecular Genetics, 1999
- A new histologic approach to the differentiation of enchondroma and chondrosarcoma of the bones. A clinicopathologic analysis of 51 cases.1985
- A New Histologic Approach to the Differentiation of Enchondroma and Chondrosarcoma of the BonesClinical Orthopaedics and Related Research, 1985